Table of Contents Author Guidelines Submit a Manuscript
Journal of Analytical Methods in Chemistry
Volume 2015, Article ID 735145, 11 pages
http://dx.doi.org/10.1155/2015/735145
Research Article

Stability-Indicating RP-HPLC Method for Simultaneous Estimation of Enrofloxacin and Its Degradation Products in Tablet Dosage Forms

1Department of Inorganic and Analytical Chemistry, Andhra University, Visakhapatnam 530003, India
2Department of Chemistry, Changwon National University, Changwon 641-773, Republic of Korea

Received 10 November 2014; Accepted 22 December 2014

Academic Editor: Josep Esteve-Romero

Copyright © 2015 V. Ashok Chakravarthy et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Bayer Animal Health, Baytril Chemistry: Scientific Discussion, Bayer Animal Health, http://www.animalhealth.bayer.com/fileadmin/media/baytril/pdf_food/kap2.pdf.
  2. N. Seedher and P. Agarwal, “Various solvent systems for solubility enhancement of enrofloxacin,” Indian Journal of Pharmaceutical Sciences, vol. 71, no. 1, pp. 82–87, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. Enrofloxacin for veterinary use, European Pharmacopoeia 8.0, European directorate for the quality medicines and health care, 2014, pp. 2137–2139.
  4. P. Altreuther, “Data on chemistry and toxicology of Baytril,” Veterinary Medical Review, vol. 2, pp. 87–89, 1987. View at Google Scholar
  5. S. A. Brown, “Fluoroquinolones in animal health,” Journal of Veterinary Pharmacology Therapeutics, vol. 19, no. 1, pp. 1–14, 1996. View at Google Scholar
  6. The European agency for the evaluation of medicinal products, Veterinary medicinesevaluation unit, EMEA/MRL/388/98-FINAL, 1998.
  7. M. A. Garcia, C. Solans, J. J. Aramayona, S. Rueda, M. A. Bregante, and A. de Jong, “Simultaneous determination of enrofloxacin and its primary metabolite, ciprofloxacin, in plasma by HPLC with fluorescence detection,” Biomedical Chromatography, vol. 13, no. 5, pp. 350–353, 1999. View at Publisher · View at Google Scholar
  8. M. J. e Souza, C. F. Bittencourt, and L. M. Morsch, “LC determination of enrofloxacin,” Journal of Pharmaceutical and Biomedical Analysis, vol. 28, no. 6, pp. 1195–1199, 2002. View at Publisher · View at Google Scholar · View at Scopus
  9. K. Tyczkowska, K. M. Hedeen, D. P. Aucoin, and A. L. Aronson, “High-performance liquid chromatographic method for the simultaneous determination of enrofloxacin and its primary metabolite ciprofloxacin in canine serum and prostatic tissue,” Journal of Chromatography—Biomedical Applications, vol. 493, no. 2, pp. 337–346, 1989. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Horie, K. Saito, N. Nose, and H. Nakazawa, “Simultaneous determination of benofloxacin, danofloxacin, enrofloxacin and ofloxacin in chicken tissues by high-performance liquid chromatography,” Journal of Chromatography B: Biomedical Sciences and Applications, vol. 653, no. 1, pp. 69–76, 1994. View at Publisher · View at Google Scholar · View at Scopus
  11. O. R. Idowu and J. O. Peggins, “Simple, rapid determination of enrofloxacin and ciprofloxacin in bovine milk and plasma by high-performance liquid chromatography with fluorescence detection,” Journal of Pharmaceutical and Biomedical Analysis, vol. 35, no. 1, pp. 143–153, 2004. View at Publisher · View at Google Scholar · View at Scopus
  12. The United States Pharmacopoeia (USP), USP 37, NF 32, United States Pharmacopeial Convention, Rochville, Md, USA, 2014.
  13. L. R. Snyder, J. J. Kirkland, and J. L. Glajch, Handbook of Practical HPLC Method Development, Wiley-Blackwell, Hoboken, NJ, USA, 2nd edition, 1997.
  14. “ICH, Q2(R1), harmonized tripartite guideline, validation of analytical procedures: text and methodology,” in Proceedings of the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, 2005.
  15. A. K. Basak, A. S. Raw, A. H. Al Hakim et al., “Pharmaceutical impurities: regulatory perspective for abbreviated new drug applications,” Advanced Drug Delivery Reviews, vol. 59, no. 1, pp. 64–72, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. M. Bakshi and S. Singh, “Development of validated stability-indicating assay methods—critical review,” Journal of Pharmaceutical and Biomedical Analysis, vol. 28, no. 6, pp. 1011–1040, 2002. View at Publisher · View at Google Scholar · View at Scopus
  17. United States Food and Drug Administration, “Guidance for industry: Analytical procedures and methods validation: chemistry, manufacturing, and controls documentation,” Draft Guidance, US Food and Drug Administration, 2001. View at Google Scholar
  18. G. A. Shabir, “Validation of high-performance liquid chromatography methods for pharmaceutical analysis: understanding the differences and similarities between validation requirements of the US Food and Drug Administration, the US Pharmacopeia and the International Conference on Harmonization,” Journal of Chromatography A, vol. 987, no. 1-2, pp. 57–66, 2003. View at Publisher · View at Google Scholar · View at Scopus
  19. Center for Drug Evaluation and Research (CDER), Reviewer Guidance: Validation of Chromatographic Methods, CMC 3, 1994.
  20. “Guidance for industry, analytical procedures and methods validation for drugs and biologics,” Draft Guidance, U.S. Department of Health and Human Services, Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), CMC, 2014.
  21. V. Ravichandran, S. Shalini, K. M. Sundramand, and H. Rajak, “Validation of analytical methods—strategies & importance,” International Journal of Pharmacy and Pharmaceutical Sciences, vol. 2, no. 3, pp. 18–22, 2010. View at Google Scholar
  22. T. Pranshu, R. P. Singh, and J. Vikash, “Validation: a critical parameter for quality control of pharmaceuticals,” Journal of Drug Delivery and Therapeutics, vol. 2, no. 3, pp. 34–40, 2012. View at Google Scholar
  23. D. R. Jenke, “Chromatographic method validation: a review of current practices and procedures. I. General concepts and guidelines,” Journal of Liquid Chromatography and Related Technologies, vol. 19, no. 5, pp. 719–736, 1996. View at Publisher · View at Google Scholar · View at Scopus
  24. D. R. Jenke, “Chromatographic method validation: a review of current practices and procedures. II. Guidelines for primary validation parameters,” Journal of Liquid Chromatography and Related Technologies, vol. 19, no. 5, pp. 737–757, 1996. View at Publisher · View at Google Scholar · View at Scopus
  25. D. R. Jenke, “Chromatographic method validation: a review of current practices and procedures. III. Ruggedness, revalidation and system suitability,” Journal of Liquid Chromatography & Related Technologies, vol. 19, no. 12, pp. 1873–1891, 1996. View at Publisher · View at Google Scholar · View at Scopus
  26. G. A. Shabir, W. John Lough, S. A. Arain, and T. K. Bradshaw, “Evaluation and application of best practice in analytical method validation,” Journal of Liquid Chromatography and Related Technologies, vol. 30, no. 3, pp. 311–333, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. J. Mark Green, “A practical guide to analytical method validation,” Analytical Chemistry, vol. 68, no. 9, pp. 305A–309A, 1996. View at Google Scholar · View at Scopus
  28. USP, “Validation of compendial methods,” in United States Pharmacopeia 37, National Formulary 32, chapter 1225, The United States Pharmacopeial Convention, Rockville, Md, USA, 2014. View at Google Scholar
  29. G. V. R. Reddy, B. V. Reddy, S. W. Haque et al., “Development and validation of a stability-indicating uplc method for rosuvastatin and its related impurities in pharmaceutical dosage forms,” Quimica Nova, vol. 34, no. 2, pp. 250–255, 2011. View at Publisher · View at Google Scholar · View at Scopus
  30. B. V. Reddy, A. P. Kumar, G. V. R. Reddy, M. Sahai, J. Sreeramulu, and J. H. Park, “Stability indicating reversed-phase high performance liquid chromatography method for determination of impurities in ofloxacin tablet formulations,” Analytical Letters, vol. 43, no. 17, pp. 2653–2662, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. V. A. Chatpalliwar, P. K. Porwal, and N. Upmanyu, “Validated gradient stability indicating HPLC method for determining diltiazem hydrochloride and related substances in bulk drug and novel tablet formulation,” Journal of Pharmaceutical Analysis, vol. 2, no. 3, pp. 226–237, 2012. View at Publisher · View at Google Scholar
  32. S. P. Biradar, T. M. Kalyankar, S. J. Wadher, R. S. Moon, and S. S. Dange, “Stability indicating HPLC method development: review,” Asian Journal of Medicinal and Analytical Chemistry, vol. 1, no. 1, pp. 21–26, 2014. View at Google Scholar
  33. K. Srinivasulu, M. N. Naidu, K. Rajasekhar, M. Veerender, and M. V. Suryanarayana, “Development and validation of a stability indicating LC method for the assay and related substances determination of a proteasome inhibitor bortezomib,” Chromatography Research International, vol. 2012, Article ID 801720, 13 pages, 2012. View at Publisher · View at Google Scholar